Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
FDA Commissioner Scott Gottlieb. Photo: Drew Angerer/Getty Images
FDA Commissioner Scott Gottlieb will announce the agency's new approach to antimicrobial resistance today, including ideas for encouraging drugmakers to come up with new antibiotics.
The details: The plan also includes steps to promote careful antibiotic stewardship in human and animal medicine, and new tools to better collect data on antimicrobial use and when pathogens become resistant.
1 big problem: The current system doesn't give pharma companies an incentive to make new antibiotics. The point is to use them sparingly enough that pathogens don't become resistant, but a drug companies’ profits depend on heavier use.
- Gottlieb is expected to discuss the need for new payment models that better promote the development of new antibiotics. These models might pay more for drug upfront, but result in savings to the system down the road.
- For example, hospitals could pay a subscription fee for access to doses of new antibiotics, which would have to be high enough to make drug companies' investment worthwhile.